Compare Dr. Reddys with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PANACEA BIOTECH - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PANACEA BIOTECH DR. REDDYS LAB/
PANACEA BIOTECH
 
P/E (TTM) x 17.1 11.2 152.9% View Chart
P/BV x 3.3 2.4 138.4% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DR. REDDYS LAB   PANACEA BIOTECH
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
PANACEA BIOTECH
Mar-19
DR. REDDYS LAB/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs2,875354 813.1%   
Low Rs1,888138 1,366.1%   
Sales per share (Unadj.) Rs930.274.6 1,247.6%  
Earnings per share (Unadj.) Rs117.46.7 1,758.0%  
Cash flow per share (Unadj.) Rs185.815.5 1,198.8%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs844.457.2 1,476.1%  
Shares outstanding (eoy) m166.0761.25 271.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.63.3 77.6%   
Avg P/E ratio x20.336.8 55.1%  
P/CF ratio (eoy) x12.815.9 80.8%  
Price / Book Value ratio x2.84.3 65.6%  
Dividend payout %17.00-   
Avg Mkt Cap Rs m395,49615,061 2,625.9%   
No. of employees `00022.02.3 949.3%   
Total wages/salary Rs m33,5621,471 2,281.9%   
Avg. sales/employee Rs Th7,032.81,973.6 356.3%   
Avg. wages/employee Rs Th1,527.9635.6 240.4%   
Avg. net profit/employee Rs Th887.7176.8 502.1%   
INCOME DATA
Net Sales Rs m154,4824,567 3,382.6%  
Other income Rs m3,37545 7,533.5%   
Total revenues Rs m157,8574,612 3,422.9%   
Gross profit Rs m31,7822,030 1,565.8%  
Depreciation Rs m11,348540 2,101.5%   
Interest Rs m8891,048 84.8%   
Profit before tax Rs m22,920486 4,714.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,85877 5,003.9%   
Profit after tax Rs m19,500409 4,766.6%  
Gross profit margin %20.644.4 46.3%  
Effective tax rate %16.815.9 106.1%   
Net profit margin %12.69.0 140.9%  
BALANCE SHEET DATA
Current assets Rs m111,1012,415 4,601.4%   
Current liabilities Rs m58,9739,077 649.7%   
Net working cap to sales %33.7-145.9 -23.1%  
Current ratio x1.90.3 708.3%  
Inventory Days Days7965 121.9%  
Debtors Days Days9471 132.8%  
Net fixed assets Rs m101,2458,333 1,214.9%   
Share capital Rs m83061 1,354.0%   
"Free" reserves Rs m139,4063,443 4,049.3%   
Net worth Rs m140,2363,504 4,002.2%   
Long term debt Rs m22,000461 4,770.2%   
Total assets Rs m224,65613,755 1,633.2%  
Interest coverage x26.81.5 1,829.6%   
Debt to equity ratio x0.20.1 119.2%  
Sales to assets ratio x0.70.3 207.1%   
Return on assets %9.110.6 85.7%  
Return on equity %13.911.7 119.1%  
Return on capital %14.938.7 38.6%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m88,6731,203 7,370.8%   
Fx outflow Rs m19,104467 4,093.8%   
Net fx Rs m69,569736 9,447.6%   
CASH FLOW
From Operations Rs m28,7041,049 2,736.8%  
From Investments Rs m-7,727-54 14,443.0%  
From Financial Activity Rs m-21,326-1,011 2,108.6%  
Net Cashflow Rs m-314-20 1,593.9%  

Share Holding

Indian Promoters % 25.5 74.5 34.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 0.6 900.0%  
FIIs % 35.3 1.3 2,715.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 23.6 64.8%  
Shareholders   75,885 10,259 739.7%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   TORRENT PHARMA  ALKEM LABORATORIES  ELDER PHARMA  SANOFI INDIA  ALEMBIC PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Flat; L&T and Tech Mahindra Top Losers(12:30 pm)

Share markets in India are presently trading on a volatile note. Sectoral indices are trading mixed with stocks in the capital goods sector and realty sector.

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 13, 2019 12:21 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS